Company profile: Eledon Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biotechnology therapies and clinical programs for organ and cellular transplantation, featuring tegoprubart, a therapeutic antibody to regulate immune response and prevent rejection. Offers the Phase 2 BESTOW kidney transplant trial, support resources for transplant patients, and R&D in ALS, xenotransplantation, and islet cell transplantation.
Products and services
- BESTOW Clinical Trial: A Phase 2 clinical study assessing tegoprubart’s effectiveness in preventing kidney transplant rejection, directly comparing outcomes against standard care in patients undergoing kidney transplantation
- Tegoprubart: An immunomodulatory therapeutic antibody engineered to regulate immune response, explicitly aimed at preventing organ transplant rejection and improving transplant viability
- Xenotransplantation Research: An animal-to-human investigative initiative examining tegoprubart’s application in xenotransplants to increase transplant viability in cross-species organ procedures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eledon Pharmaceuticals
Keystone Heart
HQ: Israel
Website
- Description: Provider of embolic cerebral protection medical devices for cardiovascular and structural heart procedures, developing and manufacturing devices that protect the brain from emboli and reduce the risk of brain infarcts during TAVR, AF ablation, and other procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keystone Heart company profile →
Envoy Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envoy Therapeutics company profile →
Pherin
HQ: United States
Website
- Description: Provider of clinical-stage investigational drugs for psychiatric and neurological disorders, particularly anxiety and depression, developing pherines (a new class of drugs) and an oral antagonist targeting the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherin company profile →
EIP Pharma
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for neurodegenerative diseases, centered on neflamapimod, an oral p38 alpha inhibitor aimed at reversing synaptic dysfunction; conducting Phase 2b trials (RewinD-LB in dementia with Lewy bodies, REVERSE-SD in early-stage Alzheimer’s) and exploring stroke recovery by enhancing neural plasticity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EIP Pharma company profile →
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eledon Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eledon Pharmaceuticals
2.2 - Growth funds investing in similar companies to Eledon Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eledon Pharmaceuticals
4.2 - Public trading comparable groups for Eledon Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →